Michael Medinger

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Joachim Drevs, Patrizia Siegert, Michael Medinger et al. · Journal of Clinical Oncology · 2007 · 302 citations

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours

K. Mross, Joachim Drevs, M Müller et al. · European Journal of Cancer · 2005 · 166 citations · Full text

Hepatology, Medicine, Liver Physiology +9

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

Joachim Drevs, Ute Zirrgiebel, C. Schmidt-Gersbach et al. · Annals of Oncology · 2005 · 120 citations

Tyrosine Kinase Inhibitor, Medicine, Receptor Tyrosine Kinase +8

Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin

Clemens Unger, B. Häring, Michael Medinger et al. · Clinical Cancer Research · 2007 · 103 citations · Full text

Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.

Joachim Drevs, Julia Fakler, S. Eisele et al. · PubMed · 2004 · 95 citations

Cancer Research, Oncology, Endothelial Cells +14